Hemostatic devices and methods of use

Abstract

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a first component having a first substrate and a second component having a second substrate. The second component is positioned within the first component. One of the first and second substrates includes a hemostatic agent and the other of the first and second substrates includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

1 - 20 . (canceled) 
     
     
         21 . An implantable medical device comprising:
 a collagen substrate;   a hemostatic agent; and   an active pharmaceutical ingredient.   
     
     
         22 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the implantable medical device comprising a coating that coats at least a portion of the collagen sheet, the coating comprising the hemostatic agent and the active pharmaceutical ingredient. 
     
     
         23 . The implantable medical device recited in  claim 22 , wherein the hemostatic agent is selected from the group consisting of epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. 
     
     
         24 . The implantable medical device recited in  claim 22 , wherein the active pharmaceutical ingredient includes rifampin and minocycline. 
     
     
         25 . The implantable medical device recited in  claim 22 , wherein:
 the hemostatic agent consists of tranexamic acid; and   the active pharmaceutical ingredient consists of rifampin and minocycline.   
     
     
         26 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the hemostatic agent and the active pharmaceutical ingredient being printed onto the collagen sheet. 
     
     
         27 . The implantable medical device recited in  claim 26 , wherein:
 the hemostatic agent consists of tranexamic acid; and   the active pharmaceutical ingredient consists of rifampin and minocycline.   
     
     
         28 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the hemostatic agent and the active pharmaceutical ingredient being sprayed onto the collagen sheet. 
     
     
         29 . The implantable medical device recited in  claim 28 , wherein:
 the hemostatic agent consists of tranexamic acid; and   the active pharmaceutical ingredient consists of rifampin and minocycline.   
     
     
         30 . The implantable medical device recited in  claim 21 , wherein:
 the substrate is a sheet made from collagen and the hemostatic agent; and   the implantable medical device comprises a coating that coats at least a portion of the sheet, the coating comprising the active pharmaceutical ingredient.   
     
     
         31 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the implantable medical device comprising a polymer that coats at least a portion of the collagen sheet, the polymer including the hemostatic agent and the active pharmaceutical ingredient. 
     
     
         32 . The implantable medical device recited in  claim 31 , wherein the polymer comprises a tyrosine-derived polyarylate, the hemostatic agent and the active pharmaceutical ingredient. 
     
     
         33 . The implantable medical device recited in  claim 32 , wherein the active pharmaceutical ingredient comprises rifampin and minocycline. 
     
     
         34 . The implantable medical device recited in  claim 31 , wherein the polymer is a tyrosine-derived polyarylate comprising a first layer including the hemostatic agent and a second layer including the active pharmaceutical ingredient. 
     
     
         35 . The implantable medical device recited in  claim 34 , wherein the active pharmaceutical ingredient comprises rifampin and minocycline. 
     
     
         36 . The implantable medical device recited in  claim 34 , wherein the second layer does not include the hemostatic agent. 
     
     
         37 . The implantable medical device recited in  claim 31 , wherein the polymer is a tyrosine-derived polyarylate comprising a first layer including the active pharmaceutical ingredient and a first amount of the hemostatic agent and a second layer including a second amount of the hemostatic agent, the second amount being different than the first amount. 
     
     
         38 . The implantable medical device recited in  claim 31 , wherein the polymer includes a first polymer defining a first layer and a second polymer defining a second layer, the first polymer including the hemostatic agent and the second polymer including the active pharmaceutical ingredient, the second polymer being different than the first polymer. 
     
     
         39 . An implantable medical device comprising:
 a sheet consisting of collagen;   a first coating that coats at least a portion of the sheet, the first coating consisting of tranexamic acid; and   a second coating that coats at least a portion of the sheet, the second coating consisting of rifampin and minocycline.   
     
     
         40 . An implantable medical device comprising:
 a sheet consisting of collagen; and   a first polymer that coats at least a portion of the sheet, the first polymer consisting of a tyrosine-derived polyarylate tranexamic acid; and   a second polymer that coats at least a portion of the sheet, the second polymer consisting of rifampin and minocycline.